GAMMA Investing LLC Purchases New Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK)

GAMMA Investing LLC purchased a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,898 shares of the company’s stock, valued at approximately $28,000.

A number of other institutional investors and hedge funds have also bought and sold shares of TAK. Lindbrook Capital LLC increased its position in shares of Takeda Pharmaceutical by 40.6% during the 4th quarter. Lindbrook Capital LLC now owns 4,065 shares of the company’s stock valued at $58,000 after purchasing an additional 1,174 shares during the last quarter. Blue Trust Inc. increased its position in shares of Takeda Pharmaceutical by 91.1% during the 4th quarter. Blue Trust Inc. now owns 5,837 shares of the company’s stock valued at $91,000 after purchasing an additional 2,782 shares during the last quarter. Allworth Financial LP increased its position in shares of Takeda Pharmaceutical by 111.2% during the 3rd quarter. Allworth Financial LP now owns 6,183 shares of the company’s stock valued at $96,000 after purchasing an additional 3,256 shares during the last quarter. Larson Financial Group LLC purchased a new stake in shares of Takeda Pharmaceutical during the 4th quarter valued at $116,000. Finally, Bruce G. Allen Investments LLC purchased a new stake in shares of Takeda Pharmaceutical during the 4th quarter valued at $138,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Down 0.1 %

Shares of Takeda Pharmaceutical stock opened at $13.36 on Tuesday. Takeda Pharmaceutical Company Limited has a 1 year low of $13.01 and a 1 year high of $17.11. The firm has a market cap of $42.28 billion, a PE ratio of 20.24, a P/E/G ratio of 3.05 and a beta of 0.56. The stock has a fifty day moving average price of $13.88 and a 200-day moving average price of $14.11. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.06 and a quick ratio of 0.55.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.